# US 7,390,508 B2 · Use of xenon with hypothermia for treating neonatal asphyxia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,390,508 B2
- Document ID: US7390508B2
- Status: Granted
- Kind: B2
- Application number: 10/573,093
- Filed: 2004-10-11
- Published: 2007-05-10
- Granted: 2008-06-24
- Earliest claimed: 2003-10-10
- Assignees: Protexeon Limited
- Inventors: Nicholas Peter Franks; Mervyn Maze
- Web page: https://patentgrep.com/patent/US7390508B2

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.

## Claims

### Claim 1

A method of treating neonatal asphyxia in a mammal in need thereof said method comprising: (a) administering to a mammal a gaseous mixture comprising xenon, the xenon having a percent concentration by volume of between about 12.5% and 50%; and (b) subjecting the mammal to hypothermia at temperatures between about 23° C. and 37° C.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the mammal is a human.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

### Claim 5 (depends on 1)

A method according to claim 1 wherein the xenon is administered simultaneously with hypothermia.

### Claim 6 (depends on 1)

A method according to claim 1 wherein the xenon is administered separately from hypothermia.

### Claim 7 (depends on 1)

A method according to claim 1 wherein the temperature of the mammal is maintained at a temperature of from about 32° C. to about 36° C.

### Claim 8 (depends on 7)

A method according to claim 7 wherein the temperature of the mammal is maintained at a temperature of from about 33° C. to about 35° C.

### Claim 9 (depends on 1)

A method according to claim 1 wherein the hypothermia is maintained for a period of at least 6 hours after the hypoxic-ischemic (HI) insult.

### Claim 10 (depends on 1)

A method according to claim 1 wherein the hypothermia is maintained for a period of from about 6 to about 24 hours after the hypoxic-ischemic (HI) insult.

### Claim 11 (depends on 1)

A method according to claim 1 wherein the xenon is administered to the mother of the mammal prior to birth.

### Claim 12 (depends on 11)

A method according to claim 11 wherein the xenon is administered to the mother of the mammal prior to, or during, labour.

### Claim 13 (depends on 11)

A method according to claim 11 wherein the xenon is administered to the mother of the mammal for up to about 24 hours prior to birth.

### Claim 14 (depends on 1)

A method according to claim 1 wherein the xenon is administered in a therapeutically effective amount.

### Claim 15 (depends on 1)

A method according to claim 1 wherein the xenon is administered in a sub-therapeutically effective amount.

### Claim 16 (depends on 1)

A method according to claim 1 wherein the xenon is administered in a combination with an anesthetic selected from the group consisting of isoflurane, sevoflurane and desfiurane.

### Claim 17

A method of treating neonatal asphyxia in a mammal in need thereof, said method comprising: (a) administering to the mother of the mammal prior to and/or during labour a gaseous mixture comprising xenon, the xenon having a percent concentration by volume of between about 12.5% and 50%; and (b) subjecting the mammal to hypothermia after birth at temperatures between about 23° C. and 37° C.

### Claim 18 (depends on 1)

The method of claim 1, wherein the xenon is administered sequentially with hypothermia.

### Claim 19 (depends on 17)

The method of claim 17, wherein the xenon is administered in a therapeutically effective amount.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the xenon is administered in a sub-therapeutically effective amount.
